Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.02 USD | -0.19% | +0.14% | -12.38% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.38% | 6.12B | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.30% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29